{
    "Trade/Device Name(s)": [
        "Capture-CMV"
    ],
    "Submitter Information": "Immucor, Inc.",
    "510(k) Number": "K183571",
    "Predicate Device Reference 510(k) Number(s)": [
        "K910003"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LJO"
    ],
    "Summary Letter Date": "December 14, 2018",
    "Summary Letter Received Date": "January 8, 2019",
    "Submission Date": "December 14, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.3175"
    ],
    "Regulation Name(s)": [
        "Cytomegalovirus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "Cytomegalovirus antibody (IgG and IgM)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NEO Iris",
        "Galileo Neo"
    ],
    "Method(s)/Technology(ies)": [
        "Solid phase red cell adherence"
    ],
    "Methodologies": [
        "Antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Capture-CMV solid phase red cell adherence test system to detect CMV antibodies in serum or plasma using NEO Iris and Galileo Neo platforms",
    "Indications for Use Summary": "Capture-CMV is an in vitro qualitative solid phase red cell adherence test system for detecting antibodies (IgG plus IgM) to cytomegalovirus in human serum or plasma, intended for screening blood and plasma donors or patients for serological evidence of previous CMV infection.",
    "fda_folder": "Microbiology"
}